Education
About Us
Working with TipRanks
Follow Us
Spyre Therapeutics, Inc (SYRE)
NASDAQ:SYRE
SYRE Stock Chart & Stats
$43.21
-$0.27(-1.11%)
At close: 4:00 PM EST
$43.21
-$0.27(-1.11%)
Day’s Range― - ―
52-Week Range$10.91 - $38.16
Previous CloseN/A
Volume84.75K
Average Volume (3M)641.88K
Market Cap
$2.84B
Enterprise Value$2.52B
Total Cash (Recent Filing)$756.53M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.72
Next Earnings
May 07, 2026EPS Estimate
-0.66Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.70
Shares Outstanding77,592,130
10 Day Avg. Volume809,945
30 Day Avg. Volume641,880
Financial Highlights & Ratios
PEG Ratio1.94
Price to Book (P/B)15.85
Price to Sales (P/S)0.00
P/FCF Ratio-66.98
Enterprise Value/Market Cap0.89
Enterprise Value/Revenue27.89
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-14.52
Forecast
1Y Price Target
$58.71Price Target Upside35.87% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-2.83
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Trial EnrollmentStrong enrollment in the SKYLINE Part A cohort and completion of a monotherapy arm supports continued data generation and reflects strong investigator interest in the program.
Combination Therapy PotentialPreclinical and translational data showing that anti-TL1A plus anti-IL-23 outperforms single agents bolster the case for Spyre's dual-targeting approach and the prospect of differentiated combination treatments in ulcerative colitis.
Financial RunwayA substantial cash position enables advancement of multiple Phase 2 programs and reduces near-term financing risk for continued development.
Bears Say
Clinical Execution RiskAnalyst rates the stock as high risk because uncertain clinical readouts and development execution could significantly affect value realization.
Incomplete Trial CohortsIncomplete enrollment in several Part A cohorts could delay proof-of-concept results and complicate development timelines.
Indication-specific UncertaintyMixed translational and clinical evidence for psoriatic arthritis and axial spondyloarthritis creates uncertainty for those indications until human proof-of-concept data confirm benefit.
Spyre Therapeutics News
SYRE FAQ
What was Spyre Therapeutics, Inc’s price range in the past 12 months?
Spyre Therapeutics, Inc lowest stock price was $10.91 and its highest was $38.16 in the past 12 months.
What is Spyre Therapeutics, Inc’s market cap?
Spyre Therapeutics, Inc’s market cap is $2.84B.
When is Spyre Therapeutics, Inc’s upcoming earnings report date?
Spyre Therapeutics, Inc’s upcoming earnings report date is May 07, 2026 which is in 74 days.
How were Spyre Therapeutics, Inc’s earnings last quarter?
Spyre Therapeutics, Inc released its earnings results on Feb 19, 2026. The company reported -$0.7 earnings per share for the quarter, beating the consensus estimate of -$0.709 by $0.009.
Is Spyre Therapeutics, Inc overvalued?
According to Wall Street analysts Spyre Therapeutics, Inc’s price is currently Undervalued.
Does Spyre Therapeutics, Inc pay dividends?
Spyre Therapeutics, Inc does not currently pay dividends.
What is Spyre Therapeutics, Inc’s EPS estimate?
Spyre Therapeutics, Inc’s EPS estimate is -0.66.
How many shares outstanding does Spyre Therapeutics, Inc have?
Spyre Therapeutics, Inc has 77,592,130 shares outstanding.
What happened to Spyre Therapeutics, Inc’s price movement after its last earnings report?
Spyre Therapeutics, Inc reported an EPS of -$0.7 in its last earnings report, beating expectations of -$0.709. Following the earnings report the stock price went up 14.282%.
Which hedge fund is a major shareholder of Spyre Therapeutics, Inc?
Currently, no hedge funds are holding shares in SYRE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Spyre Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$58.71 (35.87% Upside)
$58.71 (35.87% Upside)
Blogger Sentiment
Bullish
SYRE Sentiment 70%
Sector Average 70%
Sector Average 70%
Crowd Wisdom
Very Positive
Last 7 Days ▲ 7.5%
Last 30 Days ▲ 7.9%
Last 30 Days ▲ 7.9%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
92.81%
12-Months-Change
Fundamentals
Return on Equity
-22.03%
Trailing 12-Months
Asset Growth
27.82%
Trailing 12-Months
Company Description
Spyre Therapeutics, Inc
Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.
SYRE Stock 12 Month Forecast
Average Price Target
$58.71
▲(35.87% Upside)
Technical Analysis
EyePoint Pharmaceuticals
―
Praxis Precision Medicines
―
ARS Pharmaceuticals
―
Oculis Holding
―
Upstream Bio, Inc.
―
Ownership Overview
7.48% Insiders
22.02% Mutual Funds
54.81% Other Institutional Investors
4.40% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---